Biogen’s higher dose regimen of nusinersen, a drug for spinal muscular atrophy (SMA), demonstrated a statistically significant improvement in motor function in infants compared to a sham control group in a Phase 2/3 study. The results suggest that the higher dose regimen could be more effective in slowing neurodegeneration and provide greater clinical benefit for patients.